117 results about "Oral suspensions" patented technology

A method of treating gastric acid disorders by administering to a patient a pharmaceutical composition comprising a proton pump inhibitor (PPI) in a pharmaceutically acceptable carrier.

The present invention provides an oral solution/suspension comprising a proton pump inhibitor and at least one buffering agent. The PPI can be any substituted benzimidazole compound having H⁺,K⁺-ATPase inhibiting activity and being unstable to acid. Omeprazole and lansoprazole are the preferred PPIs for use in oral suspensions in concentrations of at least greater than 1.2 mg/ml and 0.3 mg, respectively. The liquid oral compositions can be further comprised of parietal cell activators, anti-foaming agents and/or flavoring agents. The inventive compositions can alternatively be formulated as a powder, tablet, suspension tablet, chewable tablet, capsule, effervescent powder, effervescent tablet, pellets and granules. Such dosage forms are advantageously devoid of any enteric coating or delayed or sustained-release delivery mechanisms, and comprise a PPI and at least one buffering agent to protect the PPI against acid degradation. Similar to the liquid dosage form, the dry forms can further include anti-foaming agents, parietal cell activators and flavoring agents. Kits utilizing the inventive dry dosage forms are also disclosed herein to provide for the easy preparation of a liquid composition from the dry forms. In accordance with the present invention, there is further provided a method of treating gastric acid disorders by administering to a patient a pharmaceutical composition comprising a proton pump inhibitor in a pharmaceutically acceptable carrier and at least one buffering agent wherein the administering step comprises providing a patient with a single dose of the composition without requiring further administering of the buffering agent. Additionally, the present invention relates to a method for enhancing the pharmacological activity of an intravenously administered proton pump inhibitor in which at least one parietal cell activator is orally administered to the patient before, during or after the intravenous administration of the proton pump inhibitor.

The present invention discloses a novel powder for oral suspension of cefdinir. Also disclosed are methods of preparing the suspension and methods of treatment using the suspension.

This invention relates to a powder for oral suspension, and an oral suspension made therefrom, which comprises a n-propanol solvate of non-dihydrate azithromycin and an azithromycin conversion stabilizing excipient, wherein said excipient reduces the conversion of the form of azithromycin, when placed in suspension, to another form of azithromycin.

This invention also relates to an oral suspension which comprises a n-propanol solvate of non-dihydrate azithromycin and an aqueous vehicle.

Compositions of azathioprine oral suspensions are disclosed. Disclosed azathioprine oral suspensions may be used to administer azathioprine to subjects such as children and geriatric patients that may have difficulty in swallowing solid dosage forms. The disclosed azathioprine oral suspension may be used for treating autoimmune diseases such as rheumatoid arthritis, pemphigus, Behcet's disease, autoimmune hepatitis, and inflammatory bowel disease, among others. According to an embodiment, an aqueous or non-aqueous vehicle may be used for azathioprine oral suspension. According to a different embodiment, sugar free azathioprine oral suspension may also be produced.

A drug formulation in the form of a dry powder is provided which when mixed with water forms a palatable oral suspension substantially free of bitter taste, the dry powder being formed of a drug, preferably des-quinolone, which in solution has a bitter taste, and a pH modifying agent which is preferably an alkaline material such as L-arginine, where upon mixing the dry-powder in water causes the drug to have reduced solubility or precipitate in-situ to form a palatable oral suspension essentially free of bitter taste.

An oral suspension, methods for making same and a method for masking the bitter taste of drugs employing one or more pH modifying agents are also provided.

An oral suspension comprising (a) an antibiotic composition which comprises coated micropellets and optionally one or more excipients, (b) additional excipients, and (c) a solvent, wherein said coated micropellets comprise (i) a core comprising at least one antibiotic; (ii) an inner coating comprising at least one cellulose polymer which is not an enteric coating polymer; and (iii) an outer coating comprising at least one enteric coating polymer, wherein said coated micropellets have a mean particle size of about 100 μm to about 650 μm. The oral suspension of the invention is characterized by a lack of bitter taste.

The invention discloses an oral lurasidone suspension and a preparation method thereof. The lurasidone suspension is a pharmaceutical composition which comprises lurasidone or salt thereof, a suspending aid, a wetting agent, a pH regulator, a preservative, a sweetening agent and a corrigent, wherein the particle size range of the lurasidone or salt thereof is 0.1-20 microns. The prepared oral suspension has the characteristics of being stable in quality and favorable in taste, facilitates dose distribution, and is beneficial to the acceptance of schizophrenia patients, simple in preparation method and suitable for industrial production.

The invention discloses a composition as well as a preparation method and a preparation thereof. The composition of the present invention includes nicotinamide mononucleotide, an ion exchange resin, acoating material, and a plasticizer. The preparation method comprises the following steps: preparing the drug-loaded resin particles, and coating the drug-loaded resin particles. The coated drug-loaded resin particles are mixed with other auxiliary materials to prepare corresponding dosage forms, such as oral suspension, tablets, capsules, granules, cream, ointment, facial masks and the like. Thecomposition is simple in production process, easy to amplify and produce, capable of effectively improving the stability of nicotinamide mononucleotide, accurate in dosage, lasting in effect and stable in curative effect.

The invention provides an omeprazole enteric dry suspension and a preparation method thereof, and belongs to the technical field of medicine.The enteric dry suspension is prepared from, by weight, 40%-49% of omeprazole enteric microspheres, 0%-1% of wetting agent, 45%-58% of flavoring agent and 1%-5% of suspending aid.According to the omeprazole enteric dry suspension and the preparation method thereof, a hot-melting spraying method is adopted to prepare omeprazole and a sustained-release skeleton material into sustained-release microspheres A, the sustained-release microspheres A are each sequentially wrapped with an isolation coating layer and an enteric coating layer, the wrapped microspheres A are mixed with the flavoring agent, the wetting agent and the suspending aid, and then the omeprazole enteric dry suspension is obtained; the prepared omeprazole enteric dry suspension is distributed uniformly in the intestinal tract and is not prone to cause initial burst release; compared with tablets and capsules, the omeprazole enteric dry suspension is good in stability, fractional doses are convenient, an oral suspension is formed by adding water to the dry suspension to enable the dry suspension to be dissolved, absorption is good, the efficacy is quick to achieve, the bioavailability is good, the mouthfeel is good, the dry suspension is particularly suitable for patients with dysphagia, specially for child patients and elderly patients to take, compliance of the patients is improved, and the preparation method is simple and suitable for industrial production and application.

The invention provides curcumin nano-micelle oral suspension. The curcumin nano-micelle oral suspension comprises the following active ingredients: curcumin, a chitosan nano-micelle drug carrier, a surfactant, a cosurfactant and purified water. The invention further provides curcumin nano-micelle gel. The curcumin nano-micelle oral suspension and the curcumin nano-micelle gel have good drug stability, safety and effectiveness, and can effectively treat diseases such as hyperlipidemia, sinusitis, gingivitis and cervicitis.

The invention relates to an avian decoquinate oral suspension and a preparation method thereof, belonging to the technical field of veterinary drug preparations. The avian decoquinate oral suspension comprises the following components per 100ml: 5-15g of decoquinate, 0.5-10g of surfactant, 0.1-2g of binding agent, 0.1-2g of stabilizer and 100ml of volume-metered solvent. The avian decoquinate oral suspension overcomes the defects of nonuniform stirring of premixed preparation and insufficient absorption, and can be clinically used only by dilution so that the use method is simple and convenient; and in addition, the organic solvent of the avian decoquinate oral suspension is low in content, the cost of unit preparation is effectively reduced, and the problems of high preparation cost and difficult popularization and application of the traditional preparation are solved.

An oral dosage form comprising azithromycin and an effective amount of a basifying agent. Preferably, the oral dosage form comprises an effective amount of a basifying agent and azithromycin multiparticulates, wherein the multiparticulates comprise azithromycin, a mixture of glyceryl monobehenate, glyceryl dibehenate, and glyceryl tribehenate, and porol sham. Typically, such oral dosage forms include any form suitable for oral administration such as powders for oral suspensions, unit dose sachets or sachets, tablets or capsules. Also disclosed is an oral suspension comprising azithromycin, an effective amount of a basifying agent, and a vehicle. Preferably, the azithromycin is in the form of multiparticulates, wherein the multiparticulates comprise azithromycin, a mixture of glyceryl monobehenate, glyceryl dibehenate and glyceryl tribehenate, and a poloxamer. Also disclosed is a method of reducing gastrointestinal side effects associated with administration of azithromycin to a mammal, comprising continuously administering to said mammal azithromycin and an effective amount of an alkalizing agent, wherein the incidence of gastrointestinal side effects is lower than that of an equivalent dose of azithromycin Incidence without administration of the basifying agent. Also disclosed is a method of treating a mammal in need against a bacterial or protozoan infection comprising sequentially administering to said mammal a single oral dosage form, wherein said oral dosage form comprises azithromycin and an effective amount of a basifying agent. Also disclosed are azithromycin multiparticulates comprising azithromycin, a surfactant; and a pharmaceutically acceptable carrier.

Lipoic acid pellets are described, obtained from inert cores externally coated with lipoic acid. The so obtained active cores are coated with a first layer of insulating polymeric material and then with a polymeric coat that is insoluble at the gastric pH. Pellet are then formulated pharmaceutically, for instance in jelly capsules or controlled release capsules or as oral suspensions, dispersible powders, sachets, etc.

This invention relates to a powder for oral suspension, and an oral suspension made there from, which comprises non-dihydrate azithromycin and an azithromycin conversion stabilizing excipient, wherein said excipient reduces the conversion of the form of azithromycin, when placed in suspension, to another form of azithromycin. This invention further relates to a method for reducing the conversion of a form of non-dihydrate azithromycin, in an oral suspension, by adding a surface tension reducing excipient that reduces the surface tension of the aqueous vehicle. Furthermore, this invention relates to a method for reducing the conversion of a non-dihydrate azithromycin, in an unflavored oral suspension, by raising the viscosity of the oral suspension, and in a flavored oral suspension by lowering the viscosity of the oral suspension.

The invention relates to a compound of propranolol or a medicinal salt thereof and ion exchange resin and a preparation method of the compound. The compound comprises propranolol and a salt thereof and ion exchange resin, wherein the ion exchange resin is selected from one or more of polacrilin (polacrilin), polacrilin potassium (polacrilin potassium) and sodium polystyrenesulfonate. The compound of the propranolol and the salt thereof provided by the invention can be further prepared into an oral preparation, especially an oral suspension; the bitter taste and the thrill of a propranolol medicine solution can be removed; meanwhile, the stability of the compound is greatly improved; harmful impurities are reduced when the taking compliance is improved; the product quality is improved; and the medication safety of a patient is ensured.